로딩 중…
StockDiggingStockDigging

AxoGen, Inc.

AXGN· NASDAQ
$49.85+0.97%
2026-11-02

Financials

Valuation Metrics

AxoGen, Inc.'s Market Cap is $2.65B. At end of 2025 it was $1.54B. Ranked #1984 of 3,114 in US market (top 64%), #746 of 1,472 on NASDAQ (top 51%), #121 of 203 in Health Care Equipment & Services (top 60%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$2.65B
Revenue$267M
Net Income$-32M
Total Assets$550M
Net Assets$496M
Employees622
Value
P/B5.34x
P/S9.93x
FCF Yield0.62%
Profitability
ROE-6.43%
ROA-5.80%
Op. Margin-5.17%
Revenue Growth24.32%
Financial Health
Debt Ratio10.93%
Total Debt$19M
FCF$16M
Cash$329M
Current Ratio12.02x
Performance
1Y Return124.35%
1M Return33.32%
From 52W High-5.78%
1Y MDD-33.08%
Trading
Volume1,413,192 shares
Trading Value$70M
Per Share
EPS$-0.60
BPS$9.33

Company Info

CEO Michael D. Dale
Employees 622
HQ Alachua, US

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.